various cell types, such as endothelial cells, fibroblasts, monocytes, and T lymphocytes, can secrete CXCL10. 16 In addition to its leukocyte attractant properties, CXCL10 also induces migration and proliferation of VSMCs. 17, 18 Previous studies demonstrated a role for both CXCR3 and interferon-γ in the field of arteriogenesis. Loss of CXCR3 in mice resulted in lower perfusion recovery after femoral artery ligation accompanied with lower capillary density in the ischemic calf muscle and less infiltration of macrophages and T lymphocytes in hindlimb muscles. 19 Furthermore, additional studies associated hindlimb ischemia in mice with an elevation of interferon-γ plasma levels during the first 3 days after arterial occlusion. 20 The role of CXCL10 has been studied in a mouse model for myocardial infarction (MI) where CXCL10 deficiency was associated with decreased microvascular density in the infarct and peri-infarct area after induction of MI. 21 CXCL10 has been described as a late-phase protein during perfusion recovery after hindlimb ischemia that plays a more pronounced role in vessel maturation, 11 which is known as a late step in neovascularization. In fact, similar patterns of mRNA levels of CXCR3, the receptor for CXCL10, and CXCL9, another ligand for CXCR3, could be observed in a murine model for hindlimb ischemia. 19 However, the causal role for CXCL10 in hindlimb ischemia has not been studied yet. In this study, we investigated the role of CXCL10 in arteriogenesis using a mouse model for hindlimb ischemia. We hypothesized that mice lacking CXCL10 demonstrate reduced collateral vessel formation resulting in lower perfusion recovery and that influx of inflammatory cells into the surrounding tissue is hampered.
Materials and Methods
Materials and methods are available in the online-only Supplement.
Results

CXCL10 Protein Levels in Tissue and Plasma
CXCL10 protein levels in muscle tissue of the operated limb isolated from wild-type (WT) mice changed during perfusion recovery. In both adductor (nonischemic; Figure 1A ) and peroneus (ischemic; Figure 1B ) muscle tissue, CXCL10 protein levels reached its peak at day 4 (*P<0.05 versus baseline in peroneus tissue).
CXCL10 protein levels in plasma from WT mice also changed during perfusion recovery after femoral artery ligation, although in a different pattern. At day 1, plasma levels remained at baseline levels, but at day 2 the levels increased significantly. After day 2, plasma levels dropped again toward baseline levels (P<0.05 compared with baseline, days 1, 3, and 4). At day 7, the levels seem to increase again but did not reach statistical differences compared with baseline ( Figure 1C ).
Perfusion Recovery
CXCL10
−/− mice showed decreased perfusion recovery when compared with WT mice at day 4 after ligation (WT versus CXCL10 −/− : 81±13% versus 28±5%; P=0.003) and at day 7 (WT versus CXCL10 −/− : 107±8% versus 57±12%; P=0.003; Figure 2A ). To assess whether the effect of CXCL10 is mediated via bone marrow-derived cells or tissue-derived cells, we performed femoral artery ligation in chimeras. To confirm chimerization, genomic expression of CXCL10 DNA was assessed 6 weeks after irradiation and bone marrow transplantation. An expression of the corresponding genotype of >85% was acceptable for continuation of the experiments ( Figure 2B . Chemokine (C-X-C motif) ligand 10 (CXCL10) protein levels in hindlimb tissue and plasma after femoral artery ligation. CXCL10 protein levels were determined using Luminex in hindlimb muscles of the operated limb (n=5 mice per time point; A and B) and ELISA in plasma isolated after femoral artery ligation (n=10 mice per time point; C). In hindlimb muscles, CXCL10 levels were highest at day 4, which was only significant for peroneus tissue compared with baseline and day 1 (B). In plasma, levels at day 2 were significantly higher compared with baseline, days 1, 3, and 4 (C). Data are presented as mean±SEM; *P<0.05.
perfusion recovery at days 4 and 7 (WT versus chimeras: 81±13% versus 46±4% at day 4; P=0.026 and 107±8% versus 61±6% at day 7; P<0.001; Figure 2 ). Transplantation of WT bone marrow in CXCL10 −/− mice showed significantly improved perfusion recovery at day 4 (CXCL10 −/− versus chimeras: 28±5% versus 63±4% at day 4; P<0.001 and 57±12% versus 74±6% at day 7; P=0.25; Figure 2A ) but did not fully rescue the CXCL10 −/− phenotype.
Vessel Number in Adductor and Peroneus Tissue
Because perfusion recovery depends on SMC-positive conductance vessels that bypass the occluded naïve artery, we assessed the number of α-smooth muscle actin (α-SMA)-positive vessels in the adductor muscle of the operated hindlimb (total number of α-SMA-positive vessels per section). At baseline, no differences could be observed. Compared with baseline, the number of α-SMA-positive vessels was higher in both WT and CXCL10 −/− at 4 days after ligation. However, the number of α-SMA-positive vessels in CXCL10 −/− mice was significantly lower than in WT at day 4 (WT versus CXCL10 Figure 3A ).
Although arteriogenesis in the used mouse model occurs mostly in the upper hindlimb (adductor), angiogenesis takes place in the ischemic area, that is, distal from the occlusion.
We therefore assessed the number of CD31-positive vessels in the ischemic peroneus muscle, expressed per muscle fiber. At baseline, no differences could be observed between WT and CXCL10 Figure 3B ). These data indicate that, although the initial angiogenic response was slowed down in CXCL10 −/− mice, angiogenic-related vascular growth was compensated at later time points because of degradation of angiogenic vessels in WT mice.
To further identify the role of bone marrow-derived and circulating CXCL10, vessel numbers were assessed in chimeric mice. The number of α-SMA-positive vessels is higher in WT→CXCL10 −/− chimeras compared with CXCL10 −/− →WT chimeras, although not significant ( Figure 4A ). This is in concordance with the perfusion recovery data. About the angiogenic response, no difference could be observed between the chimeras ( Figure 4B ).
Collateral Vessel Geometry
A hallmark of arteriogenesis is the enlargement of collateral vessels, where VSMCs in the vessel wall are recruited and start to accumulate and proliferate to ensure permanent vessel diameter and wall thickness enlargement. We assessed the mean vessel geometry of α-SMA-positive vessels at baseline and 4 and 7 days after surgery. Vessel geometry increased over time in both groups, but in WT this increase was more pronounced with significantly larger vessels compared with CXCL10
− Figure 5A -5E). To identify the changes in VSMC subtypes between WT and CXCL10 −/− during arteriogenesis, we calculated the percentage of desmin-positive collateral vessels. During arteriogenesis, in WT mice, more desmin-positive vessels were lost at day 4 compared with CXCL10 −/− (WT versus CXCL10 −/− : 18.5% versus 40%; P<0.001). At day 7, the percentage increased in WT mice, indicating collateral vessel maturation (WT versus CXCL10 −/− : 54% versus 32.5%; P<0.01). Simultaneously, no significant changes in percentage desmin-positive collateral vessels could be observed in CXCL10 −/− mice in time ( Figure 5G ). These data suggest that only in the WT mice transient change in VSMC subtype expression occurred during collateral vessel maturation (arteriogenesis). Collateral vessels from both WT and CXCL10 −/− mice positive for α-SMA also express the receptor for CXCL10 (CXCR3) at all time points. Figure 5H shows a representative image of CXCR3 staining by an α-SMA-positive vessel.
In chimeric mice, the mean vessel geometry of α-SMApositive vessels was also assessed and showed a small difference between the chimeras, in which WT→CXCL10 −/− chimeras displayed larger geometry compared with CXCL10 −/− ( Figure 6 ). Interestingly, the collateral vessel geometry data fully represent the differences in the perfusion recovery in all experimental groups.
→WT
Influx of Inflammatory Cells
Influx of inflammatory cells into the local muscle tissue plays a crucial role in vascular remodeling and perfusion recovery. Therefore, we analyzed the number of macrophages and T lymphocytes in the perivascular space of collateral arteries in the adductor muscle at baseline and days 4 and 7 after surgery. Indeed, compared with baseline, both macrophage and T-lymphocyte numbers increased during perfusion recovery, but no significant differences could be observed between WT and CXCL10 −/− ( Figure 3C and 3D). Influx of inflammatory cells was different between the chimeric mice. Although CXCL10 −/− →WT chimeras showed −/− chimeras showed significantly lower levels (lower than WT), suggesting a greater effect for resident CXCL10 than circulating CXCL10 in attraction of macrophages. The difference between both chimeric groups was significant (WT→CXCL10 −/− chimeras versus CXCL0 −/− →WT chimeras; 1.7±0.24 versus 2.7±0.26; P=0.01). T-lymphocyte influx showed a similar pattern, although no significant differences could be observed ( Figure 4C and 4D) .
In Vitro Migration of VSMCs
To evaluate the paracrine effects of CXCL10 on the migration of SMCs, human aortic VSMCs were seeded on a Transwell membrane and allowed to migrate for 18 hours in a gradient of recombinant human CXCL10 in different concentrations (0, 10, and 100 ng/mL). Compared with control (0 ng/mL), relative migration of VSMCs toward recombinant human CXCL10 was significantly higher for both 10 and 100 ng/mL (P<0.05 versus control; Figure 7A ). To evaluate the autocrine effects of CXCL10 on the migration of SMCs, human aortic VSMCs were seeded on a Transwell membrane and allowed to migrate for 18 hours in a gradient of 5% fetal calf serum. Knockdown of CXCL10 expression by siRNA in VSMCs significantly decreased the total number of migrated cells ( Figure 7B ). The chemoattractive effect of CXCL10 secretion by endothelial cells on the migration of VSMCs was also evaluated. Knockdown of CXCL10 in human umbilical cord endothelial cells (HUVECs), seeded in the lower chamber of a Transwell membrane, significantly reduced the migration of VSMCs from the upper chamber, toward the HUVECs in the lower chamber ( Figure 7C ). Knockdown of CXCL10 was evaluated in transfected HUVECs and VSMCs with semiquantitative polymerase chain reaction (PCR) on CXCL10 at 24 hours after transfection. Gel analysis of the PCR products revealed knockdown of CXCL10 after siRNA treatment compared with siSham in both VSMCs ( Figure 7D ) and HUVECs ( Figure 7E ).
Discussion
Arteriogenesis is known as an inflammatory process in which recruitment and proliferation of both inflammatory cells and VSMCs are important for maintaining tissue perfusion after local arterial occlusion. Chemokines are well-known key players in this process. CXCL10 has been described previously as a potent chemokine for attracting inflammatory cells, especially monocytes and T lymphocytes 12, 22 but has also been associated with angiogenesis in the ischemic myocardium after induction of MI in mice. 21 In this study, we investigated the causal role of CXCL10 for perfusion recovery in a mouse model for hindlimb ischemia.
To elucidate the role for CXCL10 in perfusion recovery, we first measured CXCL10 plasma levels and protein levels in hindlimb muscles after hindlimb ischemia in WT mice. CXCL10 levels increased significantly in ischemic muscle tissue at day 4. In nonischemic tissue, a similar trend was observed. CXCL10 plasma levels increased significantly already on day 2. Based on the general short life of chemokines, this suggests that circulating CXCL10 is involved particularly in the initiation process during the early phase after femoral artery occlusion, whereas tissue CXCL10 is involved at a later stage. To establish causality, we performed a unilateral femoral artery ligation in WT and CXCL10 −/− mice. In line with the plasma and tissue levels, perfusion recovery was reduced in CXCL10 −/− mice as early as day 4 compared with WT. This difference was still evident at day 7, when WT mice reached full perfusion recovery. This is in concordance with the study of Waeckel et al 19 using CXCR3 −/− mice in a hindlimb ischemia model.
To determine whether the role of CXCL10 relies on circulating or resident cells, we performed bone marrow transplantations in WT and CXCL10 −/− mice followed by unilateral femoral artery ligation. Transplanting CXCL10 −/− bone marrow into WT mice led to comparable reductions of perfusion recovery demonstrated by total CXCL10 −/− mice. When WT bone marrow was transplanted into CXCL10 −/− mice, perfusion recovery was significantly improved. Yet, WT bone marrow transplantation was not able to fully restore perfusion to comparable amounts as in WT mice. This indicates that CXCL10 from both circulating and resident cells is important in perfusion recovery, which is in line with the fact that leukocytes as well as endothelial cells, VSMCs, and fibroblasts can be a source for CXCL10. [16] [17] [18] To investigate the role of CXCL10 in attracting inflammatory cells during perfusion recovery, we assessed local To examine the chemoattractive function of CXCL10 on migration, VSMCs were plated on a polycarbonate Transwell filter and were allowed to migrate toward the lower chamber for 18 hours. VSMCs plated in the upper chamber migrated toward recombinant human CXCL10 (rhCXCL10; 0, 10, and 100 ng/mL) in the lower chamber. Both 10 and 100 ng/mL CXCL10 resulted in a significantly higher migration compared with control (numbers relative to control; A). siRNA-mediated knockdown of CXCL10 in VSMCs resulted in significantly less migration toward a fetal calf serum (FCS) gradient (siCXCL10 vs control or siSHAM; B). Untreated VSMCs plated in the upper chamber were allowed to migrate toward siRNA-mediated CXCL10 knockdown in human umbilical cord endothelial cells (HUVECs). Significantly fewer VSMCs migrated toward treated HUVECs after siRNA knockdown of CXCL10 (siCXCL10 vs control or siSHAM; C). siRNA-mediated knockdown was validated using semiquantitative polymerase chain reaction method for both VSMC (D) and HUVEC (E). β-Actin was used as a housekeeping gene. Data are presented as mean±SEM of 2 experiments in which each condition was performed in triplicate. *P<0.05; **P<0.01 vs control and siSHAM condition. macrophage and T-lymphocyte accumulation around collateral vessels in WT and CXCL10 −/− mice at different time points during perfusion recovery. Although we observed the expected increased influx of these cells after hindlimb ischemia, no significant differences could be observed in macrophage and T-lymphocyte accumulation between WT and CXCL10 −/− mice at any time point. Previous studies in ischemic tissues showed decreased leukocyte accumulation in CXCR3 −/− and CXCL10 −/− mice in a murine MI model. 19, 21 In the murine hindlimb ischemia model, arteriogenesis in the upper limb is initiated by shear stress and not ischemia, which might explain the differences in leukocyte recruitment. Chimeric experiments revealed a greater effect for CXCL10 expressed by tissue resident cells in the attraction of macrophages and T lymphocytes toward the tissue because CXCL10 deficiency in bone marrow alone does not influence cell influx at least in the last phase of perfusion recovery (day 7). Furthermore, transplantation of WT bone marrow in CXCL10 −/− even resulted in lower influx. Therefore, CXCL10 expressed by, for instance, VSMCs might explain inflammatory cell influx. In contrast, the vessel number and geometry measurements in chimeric mice show again a dual role for both bone marrow-derived and resident CXCL10. These latter measurements provide the strongest explanation for perfusion recovery differences in the WT and CXCL10 −/− mice. Next to this, the role of CXCL10 might be redundant in this process as other known ligands for CXCR3, CXCL9, and CXCL11 can be responsible for the attraction of inflammatory cells at the site of collateral growth. CXCL9 is known to be upregulated during hindlimb ischemia in a similar pattern as CXCL10. 11, 19 Apart from these CXCR3 ligands, there is a huge variety of factors that can attract monocytes and lymphocytes that may compensate the lack of CXCL10 in this study, which we therefore did not assess.
Because CXCL10 is known to act on both endothelial cells and SMCs, [16] [17] [18] we analyzed the number of α-SMA-positive vessels and measured collateral vessel dimensions in the hindlimb muscle. WT mice showed more α-SMA-positive vessels after femoral artery ligation than CXCL10 −/− mice. Concomitantly, enlargement of collateral vessels in WT mice during perfusion recovery is more prominent compared with CXCL10 −/− mice pointing out a role for CXCL10 in migration of VSMCs. The direct effect of CXCL10 on VSMCs is plausible because we demonstrated the expression of CXCR3 by VSMCs in the hindlimb tissue.
In addition, we further elucidated on the VSMC subtypes by analyzing desmin expression in α-SMA-positive vessels, a marker for contractile VSMCs. We observed that WT mice showed an early decrease in desmin expression (more synthetic that contractile VSMCs), followed by a later increase in vascular desmin expression (more contractile than synthetic VSMCs), which is a hallmark of arteriogenesis. However, desmin expression in CXCL10 −/− mice hardly changed. These data suggest that only the WT mice showed transient changes in VSMC subtype expression during collateral vessel maturation (arteriogenesis), a phenomenon not occurring in CXCL10 −/− mice. This points to a role of CXCL10 in the regulation of VSMC phenotype switch, already described by Wallace et al. 23 Our data showed that CXCL10 stimulated migration of VSMCs in vitro. Furthermore, knockdown of CXCL10 by siRNA in VSMCs and HUVECs resulted in reduced VSMC migration, indicating that CXCL10 is both intrinsically and extrinsically involved in VSMC migration. However, we were unable to directly show either the effect of CXCR3 on VSMC migration or the effect of CXCL10 on HUVEC migration. Yates-Binder et al 24 already showed an inhibiting effect of an interferon-inducible protein 10 peptide on endothelial cell motility and tube formation, although showing this in a different cell type (human microvascular endothelial cells versus HUVECs).
However, the arteriogenic response in the mouse model is of greater importance than the angiogenic response.
Although we did not further investigate the intracellular effect of CXCL10 on VSMCs, these intracellular effects of CXCL10 on VSMCs have already been described previously. CXCL10 effects are mediated through its specific receptor CXCR3(A). CXCR3 is a 7-transmembrane-spanning G-protein-coupled receptor. Binding of CXCL10 to CXCR3 leads to the exchange of GTP to GDP, followed by dissociation of the regulatory Gα subunit from the catalytic Gβγ subunit dimer. On activation, the G-protein subunits can activate different enzymes leading to the production of inositol phosphates, protein kinase activation, an increase in intracellular Ca2+ production and actin reorganization. Activation of the CXCR3 by CXCL10 leads to different cellular actions, such as degranulation, respiratory burst, and phagocytosis. 15, 25, 26 Finally, the role of CXCL10 has been described extensively in different mouse models for cardiovascular diseases, for example, atherosclerosis, aneurysm formation, or MI. Although this study shows a beneficial effect of CXCL10 on arteriogenesis, it should be mentioned that other animal models have shown detrimental effects of CXC10 on atherosclerotic plaque formation, 14 aneurysm formation, 27 or MI. 21 Taken together, our in vivo and in vitro data imply that a significant part of the beneficial effect of CXCL10 in perfusion recovery is mediated via regulation of vascular cells. In summary, our findings strongly point toward a predominant action of CXCL10 on VSMCs rather than on leukocyte infiltration in arteriogenesis.
In conclusion, CXCL10 is involved in perfusion recovery after unilateral femoral artery ligation in mice. CXCL10, from both circulating and resident cells, is involved in the process of perfusion recovery. CXCL10 stimulates α-SMA-positive vessel formation and growth but does not influence the influx of inflammatory cells during hindlimb ischemia. This study identifies a causal role for CXCL10 during arteriogenesis in a murine hindlimb ischemia model, probably via stimulation of α-SMA-positive cell recruitment to the collateral vasculature.
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